Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I pazopanib plus docetaxel dose-escalation study in advanced solid malignancies
NL-OMON24614Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pazopanib and docetaxel in Nonhematologic neoplasms and cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: Maximum tolerated dose. Started May 2010; status: recruiting.
02
Drugs
pazopanibdocetaxel
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on NL-OMON24614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24614.